Driven by China Biopharm Industry, Cell Culture Market to Reach $6.2 Billion in 2022: Report

Friday, December 14, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

The global market for cell culture products for use in the research, development, and production of biotherapeutic drugs is forecast to reach $6.2 billion in 2022, according to Kalorama Information.

NEW YORK, Dec. 14, 2018 /PRNewswire-PRWeb/ -- Key factors impacting market demand include healthy growth in the production

of biopharmaceuticals, the increasing availability of biosimilar products, the continued shift away from serum-containing formulations to chemically defined media, and the uptake of advanced fermentation technologies, including continuous processing and single-use technologies. The healthcare market research firm's recent report, Global Cell Culture Markets (Media, Sera, Reagents), analyzes the world market for media, sera and reagents as well as the major trends and drivers, the sixth time Kalorama has looked at this market since 2007.

The Chinese market will be a significant market driver, as biopharmaceutical producers ramp up production to meet rising domestic demand and target export markets. Additionally, Chinese biopharmaceutical companies have shown an increasing willingness to partner with experienced contract manufacturing outfits, boosting demand for more advanced media formulations.

Biopharmaceuticals may increase life expectancy, decrease disability, and reduce the need for health services. The approved drugs include hormones, blood factors, thrombolytics, vaccines, interferons, mAbs, and therapeutic enzymes. In the pharmaceutical industry, cell culture is a major foundation of biopharmaceutical development, bioprocessing, and manufacturing. As growing cells for biopharmaceutical production is slow, expensive, and complicated, optimizing cell culture development is of paramount concern to companies developing biopharmaceuticals.

Growth in the development and production of biopharmaceuticals is the most significant driver of the cell culture market. In 2017, 12 new biotherapeutics were approved for use in the US by the Food and Drug Administration (FDA). The growing demand for biopharmaceuticals stems from the demonstrable ability of biologicals to address unmet medical needs. Protein-based biopharmaceuticals are invariably produced by an initial cell culture step (upstream processing), followed by product recovery, purification, and formulation into the final product format (downstream processing). Upstream processing – the development phase of biopharmaceutical production – frequently leads to a bottleneck in getting new products on the market.

The process of developing biopharmaceuticals, which involves cell-based manufacturing, is complex and requires expertise in molecular biology, purification, and advanced chemistry. As a result, biopharmaceuticals are more difficult, time-consuming, and expensive to produce than synthetic drugs produced by traditional small molecule manufacturing techniques.

Market data provided in Global Cell Culture Markets include:

  • Global Cell Culture Market, 2012-2022
  • Global Cell Culture Market by Segment, 2012–2022 (Media, Sera, Reagents, Total)
  • Global Cell Culture Market by Region/Country, 2017 (North America, Europe, UK/Ireland, Singapore/Malaysia, Japan, Korea, China, Rest of World)
  • Global Cell Culture Market by Region/Country, 2022 (North America, Europe, UK/Ireland, Singapore/Malaysia, Japan, Korea, China, Rest of World)
  • Cell Culture Market Share by Company, 2017

In a market characterized by a high level of concentration, cell culture product suppliers can increase market share and sustain margins by partnering with pharmaceutical companies, or by acquiring smaller producers or companies that manufacture specialty products. BD Biosciences, Lonza Group, MilliporeSigma, and Thermo Fisher Scientific are among the other market leaders profiled in the report, which can be found at: https://www.kaloramainformation.com/Global-Cell-Culture-Media-Sera-Reagents-12070917/.

About Kalorama Information Kalorama Information, a division of BioInformatics Inc., supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website: https://www.kaloramainformation.com/.

Contact to inquire or purchase: Devin Holland 703-778-3080 x19 d.holland(at)kaloramainformation.com

Press Contact: Bruce Carlson 212-807-2262 bruce.carlson(at)kaloramainformation.com

 

SOURCE Kalorama Information



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store